The upside target for Nifty, based on the Fibonacci price extension, is around 12,854 in the near term. On the downside, Monday’s gap area (12,280-12,367) is likely to act as immediate support. Be with a bullish bias as long as Nifty maintains its rhythm of higher high and higher lows.

After a stellar rally on Monday, the markets are expected to build on gains today as the global markets traded higher, owing to vaccine development as well as US election clarity.

Dr Lal PathLabs announced its financial results for quarter ending September 2020 today. Non-COVID business was back to 98 per cent of last year levels in Q2FY21. Revenue increased in Q2FY21 by 18.2 per cent to Rs 431.9 crore from Rs 365 crore last year during the same quarter.

Cigniti Technologies, a global leader in independent quality engineering & software testing services, announced on Monday that it has now become a strategic quality engineering panel vendor for Toyota Motor Corporation Australia (TMCA). It would help accelerate its quality & digital transformation journey over the next 3 years.

The stock of Motherson Sumi Systems Limited has given a downward sloping trendline breakout, formed by connecting swing highs since August 2020. This breakout is confirmed by the above 50-day average volume.

 The demand in the metro cities remained muted during the quarter and has improved due to the festive season and pent-up demand. The revival in the automotive sector benefitted the business while infrastructure, oil & gas and power segments continued to see demand challenge.

Sensex closed Monday's session up by 704.37 points or 1.68 per cent from Friday’s close to end the session at 42,597.43 levels while Nifty was up by 197.50 points or 1.61 per cent at 12,461.05 levels.

Happiest Minds Technologies Ltd and AutonomIQ announced a partnership to accelerate the enterprise digital transformation journey using autonomous testing capabilities.

Alembic Pharmaceuticals Limited announced during the first half of the trading session (at around 10 am to be specific) that it has received tentative approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Palbociclib capsules, 75 mg, 100 mg, and 125 mg. 

Blue Star Limited is experiencing a gradual increase in the inflow of orders for bundled services. Presently, this order is one of the largest and fast-track projects, which is being executed by Blue Star in the factories’ segment.